Cabozantinib - CISMeF

Preferred Label : Cabozantinib;

NCIt synonyms : N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide; 1,1-Cyclopropanedicarboxamide, N'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N-(4- fluorophenyl)-; XL184;

NCIt definition : An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.;

UNII : 1C39JW444G;

InChIKey : ONIQOQHATWINJY-UHFFFAOYSA-N;

CAS number : 849217-68-1;

Chemical formula : C28H24FN3O5;

Codes from synonyms : 82;

Details

Origin ID

C52200;

UMLS CUI

C3181682;

Automatic exact mappings (from CISMeF team)
- Cabozantinib S-malate [SMS substance]
- cabozantinib [ATC Code]
CISMeF manual mappings
- Cabozantinib (substance) [SNOMED CT concept]
Currated CISMeF NLP mapping
- Cabozantinib [ICD-11 Extension code]
- Cabozantinib [SMS substance]
- cabozantinib [MeSH concept]
- cabozantinib [MeSH Supplementary Concept]
See also inter- (CISMeF)
- Product containing cabozantinib (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Cabozantinib (substance) [SNOMED CT concept]
- Product containing cabozantinib (medicinal product) [SNOMED CT concept]
- cabozantinib [MeSH Supplementary Concept]
- cabozantinib [MeSH concept]
- cabozantinib [ATC Code]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
- OS Authorized Value Terminology [NCIt concept]
- OS Total Dose Table [NCIt concept]
has_salt_form
- Cabozantinib S-malate [NCIt concept]
has_target
- Angiopoietin-1 Receptor [NCIt concept]
- BDNF/NT-3 Growth Factors Receptor [NCIt concept]
- Hepatocyte Growth Factor Receptor [NCIt concept]
- Mast/Stem Cell Growth Factor Receptor Kit [NCIt concept]
- Proto-Oncogene Tyrosine-Protein Kinase Receptor Ret [NCIt concept]
- Receptor-Type Tyrosine-Protein Kinase FLT3 [NCIt concept]
- Tyrosine-Protein Kinase Receptor UFO [NCIt concept]
- Vascular Endothelial Growth Factor Receptor 1 [NCIt concept]
- Vascular Endothelial Growth Factor Receptor 2 [NCIt concept]
- Vascular Endothelial Growth Factor Receptor 3 [NCIt concept]
is_free_acid_or_base_form_of
- Cabozantinib S-malate [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients